How does plecanatide compare to linaclotide?

Both are GC-C agonists with the same mechanism, but plecanatide has a lower incidence of diarrhea (5-6% vs 16-20% with linaclotide). Efficacy for constipation and IBS-C is comparable. Choice often depends on diarrhea tolerance and insurance coverage.

Is plecanatide safe long-term?

Plecanatide has been studied in long-term safety trials up to 72 weeks with no new safety signals. Because it is minimally absorbed systemically, drug-drug interactions are unlikely. It is generally considered safe for chronic use.

Treatment hubFDA ApprovedDeep Dive

Plecanatide Treatment Guide: Trulance, Cost and Provider Paths

In the United States, Plecanatide is an FDA-approved peptide therapy. Chronic idiopathic constipation (CIC) in adults; irritable bowel syndrome with constipation (IBS-C) in adults

Published: Apr 27, 2026Updated: Apr 27, 2026Medically reviewed: Apr 27, 2026Current

Medically Reviewed

This content was medically reviewed by Sarah Chen, MD, Board-Certified in Endocrinology, Diabetes, and Metabolism.

Last reviewed: April 27, 2026

Overview

Plecanatide is a GC-C receptor agonist approved by the FDA for chronic idiopathic constipation (CIC) and irritable bowel syndrome with constipation (IBS-C). It is structurally similar to linaclotide but has a lower incidence of diarrhea.

Approved Product Paths

Trulance

Branded plecanatide pathway. Chronic idiopathic constipation (CIC) in adults; irritable bowel syndrome with constipation (IBS-C) in adults

Benefits

•Improves complete spontaneous bowel movements in CIC
•Reduces abdominal pain and constipation in IBS-C
•Lower diarrhea rates than linaclotide in clinical trials
•Once-daily oral dosing

Side Effects & Friction

•Diarrhea (less frequent than linaclotide)
•Upper respiratory tract infection
•Sinusitis
•Abdominal distension

Administration Routes

Oral

Cost Reality

Plecanatide costs vary by brand, pharmacy, and insurance design. As an FDA-approved medication, coverage may be available but often requires prior authorization and documentation of the approved indication.

Provider Path

The highest-value next step is finding a provider experienced in anti-inflammatory who can evaluate whether Plecanatide fits the patient's clinical profile and insurance constraints.

How Plecanatide Works

Plecanatide is a 16-amino-acid peptide GC-C agonist structurally related to human uroguanylin. It acts locally in the intestine to increase fluid secretion and soften stools, with a similar mechanism to linaclotide but improved GI tolerability.

Plecanatide is a synthetic analog of uroguanylin, an endogenous peptide secreted by intestinal epithelial cells in response to food intake. It activates GC-C receptors with high affinity, stimulating fluid secretion via the same CFTR/NHE3 pathway as linaclotide.

Compared to linaclotide, plecanatide is structurally more similar to the endogenous human peptide. This may explain its improved tolerability profile, with significantly lower diarrhea rates despite equivalent efficacy.

The GC-C receptor activation increases intracellular cGMP, which opens chloride channels and inhibits sodium absorption. The net result is increased luminal water, accelerated transit, and softer stools.

Like linaclotide, plecanatide also has anti-nociceptive effects through cGMP-mediated modulation of visceral afferent signaling, improving abdominal pain in IBS-C.

Minimal systemic absorption (<0.1%) limits drug-drug interactions and systemic toxicity. The drug acts locally and is degraded by intestinal proteases.

Plecanatide may have a more favorable pH-dependent activation profile than linaclotide, with relatively greater activity in the small intestine where uroguanylin normally functions, compared to linaclotide's broader colonic activity.

Guanylate cyclase-C (GC-C)Intestinal epithelial cellsSubmucosal nociceptive fibers

Clinical Trial Evidence

IBS-C phase 3 trials

Population: Adults with IBS-C

N= 2,183

Duration: 12 weeks

Endpoint: Composite responder (≥30% pain reduction AND ≥1 CSBM/week increase)

3 mg: 30% responder rate vs 18% placebo (p<0.001)
6 mg: 27% responder rate vs 18% placebo
Rapid onset within first week
Diarrhea rate 5% (significantly lower than linaclotide's 16-20%)

CIC phase 3 trials

PMID: 27038722

Population: Adults with chronic idiopathic constipation

N= 2,639

Duration: 12 weeks

Endpoint: durable responder (≥3 CSBMs/week and increase ≥1 from baseline for 9 of 12 weeks)

3 mg: 21% responder rate vs 12% placebo (p<0.001)
Comparable efficacy to linaclotide for CIC
Low discontinuation rate due to diarrhea (1-2%)

Dosing & Administration

CIC (Trulance)Oral · Once daily

Starting: 3 mg once daily

Titration: No titration

Maintenance: 3 mg once daily

Maximum: 3 mg once daily

•Take with or without food
•Swallow tablet whole
•If a dose is missed, skip it; do not double
•Also approved for IBS-C at same dose

IBS-C (Trulance)Oral · Once daily

Starting: 3 mg once daily

Titration: No titration

Maintenance: 3 mg once daily

Maximum: 3 mg once daily

•Same administration as CIC dose
•Take with or without food

Side Effect Profile

Common

Diarrheamild5%

Significantly lower than linaclotide; usually mild and self-limiting

Upper respiratory infectionmild5%

Likely unrelated to drug

Sinusitismild4%

Likely unrelated

Abdominal distensionmild3%

Mild

Serious

Severe diarrheasevere<1%

Rare; pediatric contraindication similar to linaclotide

Contraindications & Warnings

Do Not Use

Pediatric patients ≤18 years
Mechanical GI obstruction
Hypersensitivity to plecanatide

Important Warnings

Same pediatric warning as linaclotide: avoid in patients ≤18 years due to severe dehydration risk observed in animal studies.
Diarrhea is the most common adverse effect but is milder and less frequent than with linaclotide.
Not for mechanical obstruction.
Limited pregnancy data; use only if benefits outweigh risks.

Drug Interactions

Drug	Interaction	Severity	Mechanism
None significant	Minimal systemic absorption	minor	<0.1% bioavailability; no CYP or transporter interactions expected

Monitoring Requirements

Bowel movement frequency and consistency
Abdominal pain and bloating
Signs of dehydration
Weight

How Plecanatide Compares

Diarrhea ratePlecanatide advantage

Plecanatide: 5%

Linaclotide (Linzess): 16-20%

Plecanatide is better tolerated with much lower discontinuation

EfficacyLinaclotide advantage

Plecanatide: Equivalent responder rates

Linaclotide: Equivalent

Similar clinical benefit for both IBS-C and CIC

Dosing convenienceLinaclotide advantage

Plecanatide: 3 mg once daily

Linaclotide: 145-290 mcg once daily

Both once daily; plecanatide has single dose strength

IBS-C efficacyPlecanatide advantage

Plecanatide: Responder rate 27-30%

Lubiprostone (Amitiza): Responder rate ~18%

GC-C agonists outperform chloride channel activators for IBS-C

MechanismPrucalopride (Motegrity) advantage

Plecanatide: GC-C agonist (secretory)

Prucalopride (Motegrity): 5-HT4 agonist (prokinetic)

Different mechanisms; prucalopride not approved for IBS-C in US

Evidence Quality Assessment

Overall Evidence Grade: A

A = Strong evidence from multiple large RCTs

Human RCTs: Extensive: Large phase 3 trials for IBS-C and CIC (total n>4,800)

Long-term data: Good: 12-week primary data; open-label extensions available

Real-world evidence: Growing: Increasing post-marketing experience since 2017

Regulatory status: FDA-approved for CIC and IBS-C in adults

Is Plecanatide Right for You?

Ideal Candidates

Adults with IBS-C or CIC who failed OTC therapy
Patients who discontinued linaclotide due to diarrhea
Those preferring a drug with lower GI side effect burden
Patients wanting simple once-daily dosing without meal restrictions

Avoid

Patients ≤18 years
Mechanical GI obstruction
Severe chronic diarrhea
Pregnancy (limited data)

Use With Caution

Elderly patients
Patients with cardiovascular or renal disease
Those with occupations sensitive to urgent bowel movements

Cost & Insurance Deep Dive

List Price (Monthly)

~$400-$500/month

Cash-Pay Range

$350-$500/month

Insurance Coverage Rate

~70-80% after step therapy

Prior Auth Likelihood

Moderate; often requires failure of fiber, PEG, or lubiprostone

Savings Programs

Trulance savings cardMay reduce copay to $25/month

Eligibility: Commercially insured

Not for government insurance

Patient assistanceFree for eligible patients

Eligibility: Uninsured, income ≤400% FPL

Annual application

Cost-Effectiveness Notes

•Priced similarly to linaclotide but better tolerability may reduce discontinuation costs
•Lower diarrhea rate means fewer office visits and rescue medications
•Generic competition expected in late 2020s-early 2030s
•Cost comparable to lubiprostone but superior IBS-C efficacy

Ready to find a plecanatide provider?

Use the provider matcher to compare treatment paths by state, coverage, budget, urgency, and intake mode before committing to a prescribing workflow.

Find a plecanatide provider

Progress Tracking Tools

Monitor health markers and outcomes during treatment.

Smart WiFi Body Scale

Tracks BMI, body fat %, and muscle mass — essential for monitoring GLP-1 progress over time.

$30–60View on Amazon

Digital Kitchen Food Scale

Precise gram-level portion tracking helps maximize weight loss results on GLP-1 therapy.

$10–20View on Amazon

Protein Shaker Bottle Set

Leak-proof mixing bottles for protein shakes — supports consistent protein intake on a smaller appetite.

$12–25View on Amazon

Amazon affiliate links; we may earn a small commission at no extra cost to you. See our disclosure.

Plecanatide FAQ

Sources

1. A Randomized Phase III Clinical Trial of Plecanatide, a Uroguanylin Analog, in Patients With Chronic Idiopathic Constipation.
Am J Gastroenterol • 2017
Claim type: clinical
View source →
2. FDA Information on Plecanatide
FDA • 2026
Claim type: regulatory
View source →

This content is for informational purposes only and does not constitute medical advice.